首页> 外文OA文献 >Inhibitory effect of positively charged triazine antagonists of prokinecitin receptors on the transient receptor vanilloid type-1 (TRPV1) channel
【2h】

Inhibitory effect of positively charged triazine antagonists of prokinecitin receptors on the transient receptor vanilloid type-1 (TRPV1) channel

机译:带正电的prokinecitin受体三嗪拮抗剂对瞬态受体vanilloid 1型(TRPV1)通道的抑制作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Four positively charged compounds, previously shown to produce analgesic activity by interacting with prokinecitin receptor or T-type calcium channels, were tested for their ability to inhibit capsaicin-induced elevation of intracellular Ca(2+) elevation in HEK-293 cells stably transfected with the human recombinant TRPV1, with the goal of identifying novel TRPV1 open-pore inhibitors. KYS-05090 showed the highest potency as a TRPV1 antagonist, even higher than that of the open-pore triazine 8aA inhibitor. The latter showed quite remarkable agonist/desensitizer activity at the rat recombinant TRPM8 channel. The activity of KYS-05090 and the other compounds was selective because none of these compounds was able to modulate the rat TRPA1 channel. Open-pore inhibitors of TRPV1 may be a new class of multi-target analgesics with lesser side effects, such as loss of acute pain sensitivity and hyperthermia, than most TRPV1 antagonists developed so far.
机译:测试了四种带正电荷的化合物(先前显示可通过与原促肽素受体或T型钙通道相互作用产生镇痛作用)抑制辣椒素诱导的HEK-293细胞稳定转染的细胞内Ca(2+)升高的能力。人类重组TRPV1,目的是鉴定新型TRPV1开孔抑制剂。 KYS-05090显示出最高的TRPV1拮抗剂效能,甚至比开孔三嗪8aA抑制剂的效能更高。后者在大鼠重组TRPM8通道上显示出非常显着的激动剂/脱敏剂活性。 KYS-05090和其他化合物的活性具有选择性,因为这些化合物均无法调节大鼠TRPA1通道。与迄今为止开发的大多数TRPV1拮抗剂相比,TRPV1的开孔抑制剂可能是一类新型的多靶点镇痛药,其副作用较小,例如急性疼痛敏感性和热疗反应丧失。

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号